Tag - CytoAgents

Pittsburgh biotech company wins funding for Covid-19 drug

Ziad2022-11-25T14:02:28-05:00 Pittsburgh biotech company CytoAgents has received $250,000 from the Richard King Mellon Foundation to help develop its drug candidate to treat cytokine storm, a deadly complication of Covid-19 and other upper respiratory illnesses. CytoAgents has been working on phase I and phase II clinical trials for GP1681, its existing drug candidate that even before Covid-19 had treated the immune response that causes inflammation and respiratory distress for people with severe influenza. It received a $1.6 million grant from the National...

CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

Ziad2022-11-25T14:02:38-05:00 CytoAgents awarded $1.6 million National Institutes of Health (NIH) grant to accelerate treatment for cytokine storm. Read more >>

Pittsburgh biotech firm involved in development of potential COVID-19 treatment

Ziad2022-11-25T14:02:38-05:00 CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. Read more >>

Pittsburgh biotech firm involved in development of potential COVID-19 treatment

Ziad2022-11-25T14:02:38-05:00 CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. The treatment would focus on what is called a “cytokine storm,” which is an excessive immune response that attacks the body. Read more >>